|
Evotec SE / Key word(s): Miscellaneous Evotec announces CEO transition 03-Jan-2024 / 18:24 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that CEO Dr Werner Lanthaler has informed the company, that he has decided to step down as CEO and will not continue to serve until the end of his current term, for personal reasons. The Supervisory Board has accepted his resignation from his office. Werner Lanthaler will continue to be available as a strategic advisor to the company’s Supervisory Board. Dr Mario Polywka, former COO and currently member of the Supervisory Board has agreed to step in as interim CEO. Evotec confirms guidance 2023. – End of the ad hoc release – Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49(0)151 19405058, volker.braun@evotec.com End of Inside Information 03-Jan-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Weight loss interventions may lower risk of severe infections in diabetics
Weight loss interventions could reduce the risk of severe cases of flu and other infections in people with diabetes, new research being presented at the
September 9, 2024